AbbVie has decided to call it quits with Google’s Calico Life Sciences. The move will involve layoffs affecting around 100 chemists. AbbVie will use the saved money to fund its biologics and cell and RNA therapies.
All entries for: Biologic
November 18, 2025
Merck
Layoffs
Rahway, NJ
10,000+ employees
Merck is letting go of 204 employees from its Rahway, New Jersey location, continuing its aggressive layoff spree in recent months.
Disease Area: Antiviral, Cardiology, Immune Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
November 17, 2025
Bristol Myers Squibb
Layoffs
Lawrence Township, NJ
10,000+ employees
Bristol Myers Squibb has announced another round of layoffs, affecting 110 employees at the Lawrence Township site.
Disease Area: Cardiology, Hematology, Immune Diseases, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
November 14, 2025
IO Biotech, Inc.
Neutral Outlook
Boston, MA
51-200 employees
For example, the Inflation Reduction Act (the “IRA”), which was passed in 2022, imposes inflation rebates on drug manufacturers for products reimbursed under Medicare Parts B and D if the prices of those products increase faster than inflation; and, beginning in 2026, the IRA establishes a “maximum fair price” for a fixed number of high expenditures pharmaceutical and biological products covered under Medicare Parts B and D following a price negotiation process with CMS. Similar efforts to control pharmaceutical and biological product pricing are also taking place at the state level.
Disease Area: Oncology
Drug Type: Biologic
November 14, 2025
Mersana Therapeutics, Inc.
Neutral Outlook
Cambridge, MA
1-50 employees
In August 2022, the Inflation Reduction Act, or IRA, was signed into law by President Biden. The new legislation has implications for Medicare Part D, which is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B to give them the option of paying a monthly premium for outpatient prescription drug coverage. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program.
Disease Area: Oncology
Drug Type: Biologic, Small Molecule
November 14, 2025
Actinium Pharmaceuticals, Inc
Neutral Outlook
New York, NY
1-50 employees
We currently believe that our targeted radiotherapies, which utilize biologic molecules, are less likely than small molecules to face pricing pressure and negotiation from the Inflation Reduction Act of 2022 (“IRA”), given that small molecules are at risk for pricing negotiations seven years after approval compared to eleven years for biologics with negotiated prices taking effect two years after selection.
Disease Area: Hematology, Oncology
Drug Type: Biologic
November 13, 2025
BioAtla, Inc.
Neutral Outlook
San Diego, CA
51-200 employees
Later healthcare reform initiatives culminated in the enactment of the Inflation Reduction Act (“IRA”) in August 2022, which, among other things, allows HHS to directly negotiate the selling price of a statutorily specified number of drugs and biologics each year that CMS reimburses under Medicare Part B and Part D. The negotiated price may not exceed a statutory ceiling price. Only high-expenditure single-source biologics that have been approved for at least 11 years (7 years for drugs) are eligible to be selected by CMS for negotiation, with the negotiated price taking effect two years after the selection year. For 2026, the first year in which negotiated prices become effective, CMS selected 10 high-cost Medicare Part D products in 2023, negotiations began in 2024, and the negotiated maximum fair price for each product has been announced.
Disease Area: Oncology
Drug Type: Biologic
November 13, 2025
Fate Therapeutics
Neutral Outlook
San Diego, CA
51-200 employees
The Inflation Reduction Act of 2022 (the IRA), for example, includes several provisions that may impact our business to varying degrees, including provisions that reduce the out-of-pocket spending cap for Medicare Part D beneficiaries to $2,000 starting in 2025, eliminating the prescription drug coverage gap; impose new manufacturer financial liability on certain drugs under Medicare Part D; allow the U.S. government to negotiate Medicare Part B and Part D price caps for certain high-cost drugs and biologics without generic or biosimilar competition; require companies to pay rebates to Medicare for certain drug prices that increase faster than inflation; and delay until January 1, 2032 the implementation of an HHS rebate rule that would have limited the fees that pharmacy benefit managers can charge.
Disease Area: Chronic Disease, Immune Diseases, Oncology, Rare Diseases
Drug Type: Biologic, Small Molecule